To date in Italy, the PARPi olaparib is approved by Agenzia Italiana del Farmaco (AIFA) as maintenance treatment after a complete or partial response to platinum-based chemotherapy for patients with recurrent high-grade serous ovarian carcinoma, carcinoma of the fallopian tube, or primary peritoneal carcinoma, with germline or somatic BRCA1/2 mutation [15]. The gene discussed is BRCA1; the disease is ovarian serous carcinoma.